Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Vertex Pharmaceuticals Inc (VRTX)  
$474.95 4.77 (1.01%) as of 4:30 Tue 6/4


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 260,040,000
Market Cap: 123.51(B)
Last Volume: 1,112,262 Avg Vol: 1,608,800
52 Week Range: $323.62 - $456.95
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    S&P COMPOSITE 1500     NASDAQ BIOTECHNOLOGY
    NASDAQ COMPOSITE     NASDAQ-100
    S&P 400 MIDCAP     NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  543
Guru Rank Value     : 3
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   Vertex Pharmaceuticals is a biotechnology company. Co. has clinical and research programs to develop treatment of cystic fibrosis. In addition, Co. has a pipeline of investigational therapies in other diseases where it is utilizing insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Co.'s marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 34,832 156,170 271,197 631,666
Total Sell Value $15,561,839 $65,781,555 $107,325,701 $215,119,054
Total People Sold 10 13 14 18
Total Sell Transactions 12 45 68 135
End Date 2024-03-07 2023-12-05 2023-06-06 2022-06-06

   
Records found: 3280
  Page 30 of 132  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Sachdev Amit EVP, Chief Patient Officer   •       –      –    2019-11-25 4 OE $109.14 $545,700 D/D 5,000 38,416     -
   Altshuler David EVP, Global Research and CSO   •       –      –    2019-11-25 4 AS $219.37 $857,737 D/D (3,910) 31,553     -
   Altshuler David EVP, Global Research and CSO   •       –      –    2019-11-25 4 OE $187.53 $733,242 D/D 3,910 35,463     -
   Kewalramani Reshma EVP and CMO   •       –      –    2019-11-25 4 AS $219.37 $1,029,284 D/D (4,692) 13,098     -
   Kewalramani Reshma EVP and CMO   •       –      –    2019-11-25 4 OE $187.53 $879,891 D/D 4,692 17,790     -
   Mcglynn Margaret G Director   –       •      –    2019-11-18 4 GD $0.00 $0 D/D 239 3,885     -
   Leiden Jeffrey M CEO & President   •       •      –    2019-11-18 4 AS $210.00 $931,140 D/D (4,434) 106,346     -
   Leiden Jeffrey M CEO & President   •       •      –    2019-11-18 4 OE $109.14 $517,893 D/D 4,434 107,839     -
   Arbuckle Stuart A EVPChief Commercial Officer   •       –      –    2019-11-15 4 AS $205.95 $3,913 D/D (19) 33,240     -
   Parini Michael EVP, CL&AO   •       –      –    2019-11-15 4 AS $205.95 $17,300 D/D (84) 35,003     -
   Sachdev Amit EVP, Chief Patient Officer   •       –      –    2019-11-15 4 AS $205.95 $11,739 D/D (57) 33,416     -
   Tatsis Ourania SVP, CRO   •       –      –    2019-11-15 4 AS $205.95 $1,030 D/D (5) 7,252     -
   Altshuler David EVP, Global Research and CSO   •       –      –    2019-11-15 4 AS $205.95 $12,357 D/D (60) 31,553     -
   Kewalramani Reshma EVP and CMO   •       –      –    2019-11-15 4 AS $205.95 $12,563 D/D (61) 13,098     -
   Leiden Jeffrey M CEO & President   •       •      –    2019-11-15 4 AS $210.00 $1,050,000 D/D (5,000) 106,346     -
   Leiden Jeffrey M CEO & President   •       •      –    2019-11-15 4 OE $109.14 $583,988 D/D 5,000 108,029     -
   Kewalramani Reshma EVP and CMO   •       –      –    2019-11-08 4 AS $199.00 $101,291 D/D (509) 13,098     -
   Kewalramani Reshma EVP and CMO   •       –      –    2019-11-08 4 OE $155.57 $79,185 D/D 509 13,607     -
   Altshuler David EVP, Global Research and CSO   •       –      –    2019-11-06 4 AS $196.08 $241,189 D/D (1,223) 31,553     -
   Altshuler David EVP, Global Research and CSO   •       –      –    2019-11-06 4 OE $155.57 $190,262 D/D 1,223 32,776     -
   Altshuler David EVP, Global Research and CSO   •       –      –    2019-11-04 4 AS $200.26 $827,049 D/D (4,126) 31,553     -
   Altshuler David EVP, Global Research and CSO   •       –      –    2019-11-04 4 OE $86.52 $365,117 D/D 4,126 35,679     -
   Sachdev Amit EVP, Chief Patient Officer   •       –      –    2019-11-04 4 AS $199.77 $820,795 D/D (4,097) 33,416     -
   Sachdev Amit EVP, Chief Patient Officer   •       –      –    2019-11-04 4 OE $86.52 $364,235 D/D 4,097 37,513     -
   Arbuckle Stuart A EVPChief Commercial Officer   •       –      –    2019-11-04 4 AS $201.62 $747,607 D/D (3,708) 33,240     -
  3280 Records found
  Previous  30  31  32  33  34  35  36  37  38  39  Next   
  Page 30 of 132
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us